24/7 digital support for multiple myeloma transplant patients—clear answers, when it matters most.

---

Objective

To evaluate whether an agent can support multiple myeloma (MM) patients undergoing or eligible for autologous stem cell transplantation with accessible, reliable, and clinically validated information and support safe navigation of care at home, while maintaining clinical safety and usability.

Methodology

A prospective usability pilot study with three phases:

1. Internal validation by clinicians (safety & accuracy)
2. Real-world patient use (6 weeks, home setting)
3. Post-pilot evaluation (UX surveys, log analysis, clinical review)

Application deployed on private AZ Delta cloud and co-developed by Mindoo.

Impact

• Improves access to information (24/7)
• Reduces patient uncertainty and cognitive burden
• Supports safe escalation to healthcare professionals
• Potentially reduces administrative workload for staff

Future directions

• Scale to larger patient populations
• Expand content and clinical domains
• Improve multilingual support and personalization
• Integrate more closely into clinical workflows and care pathways

General info & contact

Keywords (#): Agent, hematology care, digital health, patient support tool, continuity of care

RADar project research lead: M.Sc. Kim Denturck

Principal investigator: MD Dries Deeren

Timeline: 2026

Status: In progress / research ongoing

Partners: Mindoo

Funding: AstraZeneca